[Evaluation of cicletanine efficiency and tolerance in hypertensive patients treated with beta-blockaders].
Efficacy and tolerance of cicletanine, the first derivative of furopyridines have been studied in a 3 parallel groups double blind study; 120 essential mild hypertensive patients uncontrolled by beta blocking therapy were included. After a period of one month during which a treatment by placebo was added to beta blocking therapy, the patients were randomly allocated into 3 groups: group I (placebo: 40 patients), group II (cicletanine 50 mg/d: 41 patients), group III (cicletanine 100 mg/d: 39 patients). Eight patients were withdrawn in the group I (poor efficacy, n = 5 or unexpected event, n = 3), and one in the group III (unexpected event). At the beginning of the treatment period (DO), lying blood pressure (LBP) was respectively for groups I, II and III 171 +/- 14/104 +/- 6, 174 +/- 13/104 +/- 5, 172 +/- 15/105 +/- 6 mmHg. 171 +/- 14/104 +/- 6, 174 +/- 13/104 +/- 5, 172 +/- 15/105 +/- 6 mmHg. After 3 months of treatment LBP was respectively 168 +/- 21/97 +/- 10, 151 +/- 12/85 +/- 7, 147 +/- 14/82 +/- 9 mmHg. A significant treatment effect (p less than 0.001) was observed on SBP with groups II and III only, and on DBP with the 3 groups. This lowering effect was comparable in groups II and III, and greater (p less than 0.001) in these groups than in group I. At the end of this study the percentage of patients whose BP was normalized was respectively for groups I, II and III: 5 p. 100, 51 p. 100 and 74 p. 100. Clinical and biological tolerance were good.(ABSTRACT TRUNCATED AT 250 WORDS)